Drug Trial Radar · NCT05104892
Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma
Last checked: Nov 20, 2026Latest source record: Mar 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
196
Actual
Start
Dec 12, 2021
Primary completion
Feb 6, 2024
Study completion Feb 28, 2024
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel, treatment, Phase 2, double-blind, 2 arm, 12-week Proof of Concept (PoC) study with 2 staggered cohorts (2 arms in each cohort) that is designed to assess the efficacy, safety, and tolerability of rilzabrutinib in adult participants (aged 18-70 years) with moderate-to-severe asthma who are not well controlled on ICS/LABA therapy. Study treatment includes investigational medicinal product (IMP) (rilzabrutinib or placebo) added-on to a background therapy of ICS/LABA (fluticasone/salmeterol \[non-investigational medicinal product\], standardized at screening). Background therapy of ICS/LABA will be withdrawn during the 12week randomized treatment period and resumed at the end of the IMP treatment period, as outlined below: * Screening period (4 weeks) * Randomized IMP treatment period (12 weeks ± 3 days) * Background therapy stabilization phase (4 weeks) * Background therapy withdrawal phase (4-5 weeks) * No background therapy phase (3-4 weeks) * Post IMP treatment safety follow-up period (4 weeks ± 3 days)
Conditions
- Asthma
Interventions
RilzabrutinibDrug
Pharmaceutical form: Tablet Route of administration: Oral
placeboDrug
Pharmaceutical form: Tablet Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with an LOAC event during the treatment periodTime frame: Until Week 12
Locations
51 sites in 13 countries. Site status is shown where the registry gives one.
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 0320005
Ciudad Autonoma Buenos Aires, Argentina
Investigational Site Number : 0320002
Ciudad Autonoma Buenos Aires, Argentina
Investigational Site Number : 0320004
Berazategui, Buenos Aires, Argentina
Investigational Site Number : 0320006
CABA, Buenos Aires, Argentina
Investigational Site Number : 0320003
CABA, Buenos Aires, Argentina
Investigational Site Number : 1000004
Kozloduy, Bulgaria
Investigational Site Number : 1000001
Rousse, Bulgaria
Investigational Site Number : 1000003
Sevlievo, Bulgaria
Investigational Site Number : 1000002
Sofia, Bulgaria
Investigational Site Number : 1240006
Vancouver, British Columbia, Canada
Investigational Site Number : 1240005
Waterloo, Ontario, Canada
Investigational Site Number : 1520005
Curicó, Maule Region, Chile
Investigational Site Number : 1520002
Talca, Maule Region, Chile
Investigational Site Number : 1520007
Santaigo, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520004
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520003
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520006
Quillota, Valparaiso, Chile
Investigational Site Number : 6420001
Düsseldorf, Germany
Investigational Site Number : 3480001
Edelény, Hungary
Investigational Site Number : 3480004
Hajdunánás, Hungary
Investigational Site Number : 3480003
Pécs, Hungary
Investigational Site Number : 4840003
Durango, Mexico
Investigational Site Number : 4840004
Veracruz, Mexico
Investigational Site Number : 4840001
Guadalajara, Jalisco, Mexico
Investigational Site Number : 4840002
Monterrey, Nuevo León, Mexico
Investigational Site Number : 4840005
San Juan del Río, Querétaro, Mexico
Investigational Site Number : 6160005
Bialystok, Poland
Investigational Site Number : 6160002
Krakow, Poland
Investigational Site Number : 6160010
Lodz, Poland
Investigational Site Number : 6160001
Lodz, Poland
Investigational Site Number : 6160009
Poznan, Greater Poland Voivodeship, Poland
Investigational Site Number : 6160007
Lublin, Lubusz Voivodeship, Poland
Investigational Site Number : 6160003
Bialystok, Podlaskie Voivodeship, Poland
Investigational Site Number : 6160006
Gdansk, Pomeranian Voivodeship, Poland
Investigational Site Number : 6160008
Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, Poland
Investigational Site Number : 6420002
Cluj-Napoca, Romania
Investigational Site Number : 4100001
Seoul, South Korea
Investigational Site Number : 4100007
Daegu, Daegu, South Korea
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.